Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
70
RLAY Quote, Financials, Valuation and Earnings
Last price:
$10.16
Seasonality move
:
-27.21%
Day range:
$9.55 - $10.25
52-week range:
$1.78 - $11.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
110.05x
P/B ratio:
3.01x
Volume:
2.7M
Avg. volume:
2.5M
1-year change:
218.18%
Market cap:
$1.7B
Revenue:
$15.4M
EPS (TTM):
-$1.61
Analysts' Opinion
-
Consensus RatingRelay Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.64, Relay Therapeutics, Inc. has an estimated upside of 58.75% from its current price of $10.15.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing -31.98% downside risk from its current price of $10.15.
Fair Value
-
According to the consensus of 10 analysts, Relay Therapeutics, Inc. has 58.75% upside to fair value with a price target of $15.64 per share.
RLAY vs. S&P 500
-
Over the past 5 trading days, Relay Therapeutics, Inc. has overperformed the S&P 500 by 8.75% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Relay Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Relay Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Relay Therapeutics, Inc. reported revenues of $7M.
Earnings Growth
-
Relay Therapeutics, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Relay Therapeutics, Inc. reported earnings per share of -$0.32.
Enterprise value:
1.2B
EV / Invested capital:
1.98x
Price / LTM sales:
110.05x
EV / EBIT:
--
EV / Revenue:
77.18x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$11.8M
Return On Assets:
-37.46%
Net Income Margin (TTM):
-1800.46%
Return On Equity:
-41.4%
Return On Invested Capital:
-39.11%
Operating Margin:
-866.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $25.5M | $10M | $15.4M | -- | $7M | |
| Gross Profit | $20.3M | $4.5M | $11.8M | -$1.3M | $6.4M | |
| Operating Income | -$379.4M | -$385.7M | -$302.7M | -$85M | -$60.6M | |
| EBITDA | -$374.2M | -$380.2M | -$299.2M | -$83.6M | -$60M | |
| Diluted EPS | -$2.79 | -$2.40 | -$1.61 | -$0.45 | -$0.32 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $976.2M | $1B | $770.1M | $809.2M | $578.3M | |
| Total Assets | $1B | $1.1B | $844M | $871.3M | $621.3M | |
| Current Liabilities | $24.3M | $63.7M | $30.3M | $50.7M | $25.6M | |
| Total Liabilities | $110.6M | $149.6M | $92M | $93.5M | $54.3M | |
| Total Equity | $897.8M | $950.2M | $752M | $777.8M | $567.1M | |
| Total Debt | $21.1M | $53.5M | $48.5M | $42.8M | $28.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$300.3M | -$249.1M | -$235.5M | -$57.9M | -$44.9M | |
| Cash From Investing | $257.6M | -$41.1M | $192.8M | $29M | $35.5M | |
| Cash From Financing | $34.8M | $270.2M | $1.6M | $800K | $934K | |
| Free Cash Flow | -$304.4M | -$251.1M | -$235.9M | -$57.9M | -$44.9M | |
RLAY
Sector
Market Cap
$1.7B
$25.3M
Price % of 52-Week High
86.21%
49.41%
Dividend Yield
0%
0%
Shareholder Yield
0.13%
-1.6%
1-Year Price Total Return
207.81%
-17.71%
Beta (5-Year)
1.551
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.57
200-day SMA
Buy
Level
$5.76
Bollinger Bands (100)
Buy
Level
6.81 - 8.77
Chaikin Money Flow
Sell
Level
-2.3M
20-day SMA
Buy
Level
$9.12
Relative Strength Index (RSI14)
Buy
Level
65.54
ADX Line
Buy
Level
24.27
Williams %R
Neutral
Level
-51.2243
50-day SMA
Buy
Level
$8.47
MACD (12, 26)
Buy
Level
2.66
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
8.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.1555)
Sell
CA Score
(Annual)
Level (-0.4454)
Buy
Beneish M-Score
(Annual)
Level (-3.6907)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (7.286)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, RLAY has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RLAY average analyst price target in the past 3 months is $15.64.
-
Where Will Relay Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Relay Therapeutics, Inc. share price will rise to $15.64 per share over the next 12 months.
-
What Do Analysts Say About Relay Therapeutics, Inc.?
Analysts are divided on their view about Relay Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Relay Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Relay Therapeutics, Inc.'s Price Target?
The price target for Relay Therapeutics, Inc. over the next 1-year time period is forecast to be $15.64 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RLAY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Relay Therapeutics, Inc. is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RLAY?
You can purchase shares of Relay Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Relay Therapeutics, Inc. shares.
-
What Is The Relay Therapeutics, Inc. Share Price Today?
Relay Therapeutics, Inc. was last trading at $10.16 per share. This represents the most recent stock quote for Relay Therapeutics, Inc.. Yesterday, Relay Therapeutics, Inc. closed at $10.15 per share.
-
How To Buy Relay Therapeutics, Inc. Stock Online?
In order to purchase Relay Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RLAY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RLAY
Sector
P/E ratio
--
22.85x
PEG ratio
--
-0.01x
P/B ratio
3.01x
1.78x
Price / LTM sales
110.05x
1.52x
Growth Metrics
RLAY
Sector
Revenue growth
-23.26%
3.33%
Earnings growth
30.32%
11.64%
Revenue (5-year growth)
-28.58%
6.41%
Earnings forecast
-$0.40
-$0.20
Profitability
RLAY
Sector
Profitability FY 2025
$11.8M
$2.3M
Return on invested capital
-39.11%
-33.31%
Return on assets
-37.46%
-29.79%
Return on equity
-41.4%
-38.98%
Earnings Date
Last Earnings Date
Feb
26
Next Earnings Date
May
4
Estimated Next Earnings Date
May
28
Balance Sheet
RLAY
Sector
Total cash
$554.5M
$24.1M
Short term investments
$657M
$23.8M
Total assets
$621.3M
$70.1M
Long term debt
$28.7M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 5
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Sell
36
PSIX alert for Mar 5
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
Sell
49
TREE alert for Mar 5
LendingTree, Inc. [TREE] is up 1.11% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
